Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPHIA: Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer
NCT02492711Phase 3Completed
- Sponsor
- MacroGenics
- Start
- Aug 2015
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of margetuximab in breast cancer (3 arms), sponsored by MacroGenics. Primary endpoints: Progression-free Survival at 5 months, Overall Survival at 21 months and 1 more. Started Aug 2015; status: completed.
02
Drugs
margetuximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02492711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492711.